外源性雌激素与头颈部肿瘤发生的关系
这项大型多中心队列研究利用TriNetX真实世界数据库20年数据,纳入87家医疗机构的女性患者。口服避孕药者头颈部肿瘤诊断风险较高(RR 1.47),绝经后激素替代治疗者风险较低(RR 0.77)。
要点
- 口服避孕药女性头颈部肿瘤诊断风险较未使用者升高(RR 1.47)。
- 绝经后激素替代治疗女性头颈部肿瘤诊断风险较未使用者降低(RR 0.77)。
- 作者指出因TriNetX数据库局限,未来研究需纳入用药详情与生殖健康信息。
核心结论
- 口服避孕药与女性头颈部肿瘤发生呈正相关,激素替代治疗与头颈部肿瘤发生呈负相关。
- 作者指出鉴于TriNetX数据库的局限性,未来研究应纳入口服避孕药和激素替代治疗的详细用药信息及生殖健康信息(如初潮/绝经年龄、妊娠次数),以更准确界定外源性雌激素暴露与女性头颈部肿瘤发生之间可能关联的强度和方向。
研究设计与样本
- 大型多中心队列研究,使用TriNetX真实世界数据库截至2023年5月31日的20年数据,来自87家医疗机构。
- 队列1为18至45岁规律口服避孕药的女性731366例,队列2为同年龄段未使用口服避孕药者3886568例。
- 队列3为至少50岁接受激素替代治疗的女性135875例,队列4为至少50岁未接受激素替代治疗者5875270例。
- 对年龄、酒精依赖和尼古丁依赖进行倾向性评分匹配,数据分析于2023年5月进行。
主要发现
- 倾向性评分匹配后,队列1和队列2各纳入718101例女性(诊断时平均[SD]年龄25.9[6.7]岁),口服避孕药者头颈部肿瘤诊断风险高于未使用者(RR 1.47;95%CI 1.21-1.78)。
- 倾向性评分匹配后,队列3和队列4各纳入131835例女性(平均[SD]年龄67.9[12.0]岁),绝经后激素替代治疗者头颈部肿瘤诊断风险低于未使用者(RR 0.77;95%CI 0.64-0.92)。
关键数值与推荐
- 头颈部肿瘤诊断依据国际疾病分类第十版编码C00-C14。
- 倾向性评分匹配采用1:1最近邻贪婪匹配法。
- 风险分析报告风险差异和风险比(RR)及其95%CI。
局限性
- 作者指出鉴于TriNetX数据库的局限性,未来研究应纳入口服避孕药和激素替代治疗的详细用药信息及生殖健康信息(如初潮/绝经年龄、妊娠次数)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Sex differences in head and neck cancer (HNC) incidence suggest a potential contribution of sex hormones. OBJECTIVE: To assess the role of exogenous estrogen exposure in the development of HNC in female patients. DESIGN, SETTINGS, AND PARTICIPANTS: This large multicenter cohort study using clinical records from the TriNetX real-world database included 20 years of data (through May 31, 2023) from 87 health care organizations. The TriNetX database was searched for medical records for female patients with and without exogenous estrogen exposure according to their chronological age. Cohort 1 included 731 366 female patients aged 18 to 45 years old with regular oral contraceptive (OC) intake and cohort 2 included 3 886 568 patients in the same age group who did not use OC. Cohort 3 comprised 135 875 female patients at least 50 years old receiving hormone replacement therapy (HRT), whereas cohort 4 included 5 875 270 patients at least 50 years old without HRT. Propensity score matching was performed for the confounders age, alcohol dependence, and nicotine dependence. Data analyses were performed in May 2023. MAIN OUTCOME AND MEASURES: Diagnosis of HNC (International Statistical Classification of Diseases and Related Health Problems, Tenth Revision: C00-C14), and after propensity score matching (1:1 nearest-neighbor greedy matching), a risk analysis to investigate risk differences and risk ratios (RRs) with a 95% CI. RESULTS: Among the 718 101 female patients in each of cohorts 1 and 2 (mean [SD] age at diagnosis, 25.9 [6.7] years), those with OC intake had a higher risk of an HNC diagnosis (RR, 1.47; 95% CI, 1.21-1.78) than those without OC use. Among the 131 835 female patients in each of cohorts 3 and 4 (mean [SD] age, 67.9 [12.0] years), those with postmenopausal HRT intake had a lower risk of an HNC diagnosis (RR, 0.77; 95% CI, 0.64-0.92) than those without HRT use. CONCLUSIONS AND RELEVANCE: The findings of this cohort study illustrate a positive association between OC and a negative association between HRT and the development of HNC in female patients. Given the limitations of the TriNetX database, future research should include detailed information on the intake of OC and HRT and reproductive health information (eg, age at menarche/menopause, number of pregnancies) to more accurately define the strength and direction of the possible association between exogeneous estrogen exposure and the development of HNC in female patients.
引用
- Doll C, Hofmann E, Preissner R, et al. Exogenous Estrogen in the Development of Head and Neck Cancer. JAMA Otolaryngol Head Neck Surg. 2024. PMID: 38546631. doi:10.1001/jamaoto.2023.4739
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。